Plasma coenzyme Q10 levels and prostate cancer risk: The Multiethnic Cohort Study

Weiwen Chai, Robert V. Cooney, Adrian A. Franke, Christian P. Caberto, Lynne R. Wilkens, Loïc Le Marchand, Marc T. Goodman, Brian E. Henderson, Laurence N. Kolonel

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Coenzyme Q10 (CoQ10) is considered to be a potential anticancer agent, but epidemiologic evidence regarding CoQ10 and prostate cancer risk is lacking. We examined the association of circulating CoQ10 levels with prostate cancer risk, using prediagnostic blood samples. Methods: Each of the 307 cases was individually matched to approximately 2 controls, for a total of 596 controls, on age, ethnicity, geographic location, date/time of specimen collection, and hours of fasting. Logistic regression was used to compute ORs and 95% CIs. Results: There was no overall statistically significant association of plasma CoQ10 levels with prostate cancer risk (Ptrend = 0.50). However, after matched sets in which controls who had possible undiagnosed prostate cancer (prostate specific antigen value >4.0) were excluded, the ORs for quintiles 2 to 5 were all less than 1.0. Conclusions: The results suggest the possibility that moderate levels of circulating CoQ10 may be optimal for the reduction of prostate cancer risk; however, the findings were weak and not statistically significant. Because this is the first epidemiologic study of the association between CoQ10 and prostate cancer, further research on this topic is needed. Impact: If a nutritional factor such as CoQ10 were determined to reduce prostate cancer risk, it would have considerable public health significance because of the very high incidence of this cancer.

Original languageEnglish (US)
Pages (from-to)708-710
Number of pages3
JournalCancer Epidemiology Biomarkers and Prevention
Volume20
Issue number4
DOIs
StatePublished - Apr 1 2011

Fingerprint

coenzyme Q10
Prostatic Neoplasms
Cohort Studies
Specimen Handling
Geographic Locations
Prostate-Specific Antigen

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Chai, W., Cooney, R. V., Franke, A. A., Caberto, C. P., Wilkens, L. R., Le Marchand, L., ... Kolonel, L. N. (2011). Plasma coenzyme Q10 levels and prostate cancer risk: The Multiethnic Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 20(4), 708-710. https://doi.org/10.1158/1055-9965.EPI-10-1309

Plasma coenzyme Q10 levels and prostate cancer risk : The Multiethnic Cohort Study. / Chai, Weiwen; Cooney, Robert V.; Franke, Adrian A.; Caberto, Christian P.; Wilkens, Lynne R.; Le Marchand, Loïc; Goodman, Marc T.; Henderson, Brian E.; Kolonel, Laurence N.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 20, No. 4, 01.04.2011, p. 708-710.

Research output: Contribution to journalArticle

Chai, W, Cooney, RV, Franke, AA, Caberto, CP, Wilkens, LR, Le Marchand, L, Goodman, MT, Henderson, BE & Kolonel, LN 2011, 'Plasma coenzyme Q10 levels and prostate cancer risk: The Multiethnic Cohort Study', Cancer Epidemiology Biomarkers and Prevention, vol. 20, no. 4, pp. 708-710. https://doi.org/10.1158/1055-9965.EPI-10-1309
Chai, Weiwen ; Cooney, Robert V. ; Franke, Adrian A. ; Caberto, Christian P. ; Wilkens, Lynne R. ; Le Marchand, Loïc ; Goodman, Marc T. ; Henderson, Brian E. ; Kolonel, Laurence N. / Plasma coenzyme Q10 levels and prostate cancer risk : The Multiethnic Cohort Study. In: Cancer Epidemiology Biomarkers and Prevention. 2011 ; Vol. 20, No. 4. pp. 708-710.
@article{ce7de4d3a90448b28d2a2c68fa38f062,
title = "Plasma coenzyme Q10 levels and prostate cancer risk: The Multiethnic Cohort Study",
abstract = "Background: Coenzyme Q10 (CoQ10) is considered to be a potential anticancer agent, but epidemiologic evidence regarding CoQ10 and prostate cancer risk is lacking. We examined the association of circulating CoQ10 levels with prostate cancer risk, using prediagnostic blood samples. Methods: Each of the 307 cases was individually matched to approximately 2 controls, for a total of 596 controls, on age, ethnicity, geographic location, date/time of specimen collection, and hours of fasting. Logistic regression was used to compute ORs and 95{\%} CIs. Results: There was no overall statistically significant association of plasma CoQ10 levels with prostate cancer risk (Ptrend = 0.50). However, after matched sets in which controls who had possible undiagnosed prostate cancer (prostate specific antigen value >4.0) were excluded, the ORs for quintiles 2 to 5 were all less than 1.0. Conclusions: The results suggest the possibility that moderate levels of circulating CoQ10 may be optimal for the reduction of prostate cancer risk; however, the findings were weak and not statistically significant. Because this is the first epidemiologic study of the association between CoQ10 and prostate cancer, further research on this topic is needed. Impact: If a nutritional factor such as CoQ10 were determined to reduce prostate cancer risk, it would have considerable public health significance because of the very high incidence of this cancer.",
author = "Weiwen Chai and Cooney, {Robert V.} and Franke, {Adrian A.} and Caberto, {Christian P.} and Wilkens, {Lynne R.} and {Le Marchand}, Lo{\"i}c and Goodman, {Marc T.} and Henderson, {Brian E.} and Kolonel, {Laurence N.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1158/1055-9965.EPI-10-1309",
language = "English (US)",
volume = "20",
pages = "708--710",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Plasma coenzyme Q10 levels and prostate cancer risk

T2 - The Multiethnic Cohort Study

AU - Chai, Weiwen

AU - Cooney, Robert V.

AU - Franke, Adrian A.

AU - Caberto, Christian P.

AU - Wilkens, Lynne R.

AU - Le Marchand, Loïc

AU - Goodman, Marc T.

AU - Henderson, Brian E.

AU - Kolonel, Laurence N.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Background: Coenzyme Q10 (CoQ10) is considered to be a potential anticancer agent, but epidemiologic evidence regarding CoQ10 and prostate cancer risk is lacking. We examined the association of circulating CoQ10 levels with prostate cancer risk, using prediagnostic blood samples. Methods: Each of the 307 cases was individually matched to approximately 2 controls, for a total of 596 controls, on age, ethnicity, geographic location, date/time of specimen collection, and hours of fasting. Logistic regression was used to compute ORs and 95% CIs. Results: There was no overall statistically significant association of plasma CoQ10 levels with prostate cancer risk (Ptrend = 0.50). However, after matched sets in which controls who had possible undiagnosed prostate cancer (prostate specific antigen value >4.0) were excluded, the ORs for quintiles 2 to 5 were all less than 1.0. Conclusions: The results suggest the possibility that moderate levels of circulating CoQ10 may be optimal for the reduction of prostate cancer risk; however, the findings were weak and not statistically significant. Because this is the first epidemiologic study of the association between CoQ10 and prostate cancer, further research on this topic is needed. Impact: If a nutritional factor such as CoQ10 were determined to reduce prostate cancer risk, it would have considerable public health significance because of the very high incidence of this cancer.

AB - Background: Coenzyme Q10 (CoQ10) is considered to be a potential anticancer agent, but epidemiologic evidence regarding CoQ10 and prostate cancer risk is lacking. We examined the association of circulating CoQ10 levels with prostate cancer risk, using prediagnostic blood samples. Methods: Each of the 307 cases was individually matched to approximately 2 controls, for a total of 596 controls, on age, ethnicity, geographic location, date/time of specimen collection, and hours of fasting. Logistic regression was used to compute ORs and 95% CIs. Results: There was no overall statistically significant association of plasma CoQ10 levels with prostate cancer risk (Ptrend = 0.50). However, after matched sets in which controls who had possible undiagnosed prostate cancer (prostate specific antigen value >4.0) were excluded, the ORs for quintiles 2 to 5 were all less than 1.0. Conclusions: The results suggest the possibility that moderate levels of circulating CoQ10 may be optimal for the reduction of prostate cancer risk; however, the findings were weak and not statistically significant. Because this is the first epidemiologic study of the association between CoQ10 and prostate cancer, further research on this topic is needed. Impact: If a nutritional factor such as CoQ10 were determined to reduce prostate cancer risk, it would have considerable public health significance because of the very high incidence of this cancer.

UR - http://www.scopus.com/inward/record.url?scp=79955784411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955784411&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-10-1309

DO - 10.1158/1055-9965.EPI-10-1309

M3 - Article

C2 - 21297042

AN - SCOPUS:79955784411

VL - 20

SP - 708

EP - 710

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 4

ER -